ClinicalTrials.gg
Sign In
RecruitingNCT07740239COSMOS-IUpdated Jul 31, 2026

A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial

An observational study in Pelvic Fracture, Prostate Cancer and Lung Cancer, sponsored by Tampere University Hospital. Recruiting at 1 site in Finland. Open to male participants. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Tampere University Hospital · Observational

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
2,050
Sex
Male
01

Study summary

The objective of this prospective multicentre study that recruits altogether 1500 older patients from the university hospitals of Tampere, Kuopio, and Oulu is to explore the clinical significance and detection of causes of generalized vulnerability. The objectives are:

O1 - Establish the prevalence of causes of generalized vulnerability among patients diagnosed with severe yet non-malignant diseases and local/locally advanced and advanced cancers, O2 - Study how causes of generalized vulnerability affect the time between the diagnosis and the adoption of a fully palliative treatment line, overall survival, and patient-reported quality of life in older adults severe diseases, and O3 - Evaluate how screening tools commonly used in patients without cancer perform in screening for causes of vulnerability in older adults with cancer

02

Conditions studied

  • Pelvic Fracture
  • Prostate Cancer
  • Lung Cancer
  • Brain Metastasis
  • Chronic Subdural Hematoma
03

In context

Hip Fractures

842 studies on the registry are indexed under Hip Fractures; 165 are open to participants now.

This study's planned enrollment of 2,050 is above the median of 149 across 280 observational studies indexed under Hip Fractures.

Browse Hip Fractures studies →

Lead sponsor

Tampere University Hospital is the lead sponsor of 212 studies on the registry; 56 are open to participants now.

Browse Tampere University Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

  • Patients with local, locally advanced and metastatic prostate cancer (n=300)
  • Patients with locally advanced and metastatic lung cancer (n=300)
  • Patients with brain metastasis (n=300)
  • Patients with chronic subdural hematoma (n=300)
  • Patients receiving high-dose chemotherapy and stem cell transplantion

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suspected or diagnosed disease
  • ≥60 years old patients, except for patients receiving high-dose chemotherapy and stem cell transplantion who need to be ≥18 years old
  • Cross-sectional imaging maximum 45 days prior to consenting or before the next treatment line
  • Patients with cancer (other than patients with prostate cancer treated with hormonal treatment before radiation treatment): study procedures (excluding image analyses) must have been carried out maximum 1 month prior to the start of a new treatment line
  • Patients with prostate cancers receiving hormonal treatment before radiation treatment): study procedures (excluding image analyses) must be carried out maximum 3 months after the start of hormonal treatment
  • Patients with other conditions: study procedures (excluding image analyses) must have been carried out maximum 4 days after the start of the hospitalization

Exclusion criteria

Exclusion Criteria:

  • Not willing or unable to give written consent
  • Patient not deemed suitable for the study by the researcher approaching the patient
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
2,050 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prostate Cancer

    Other: Test set to determine vulnerability

  • Lung Cancer

    Other: Test set to determine vulnerability

  • Pelvic Fracture

    Other: Test set to determine vulnerability

  • Chronic Subdural Hematoma

    Other: Test set to determine vulnerability

  • Brain Metastasis

    Other: Test set to determine vulnerability

  • High-dose Chemotherapy and Stem Cell Transplant

    Other: Test set to determine vulnerability

Interventions

  • OtherTest set to determine vulnerability

    This is a prospective observational study.

06

What researchers measure

Primary outcomes

  1. Detected cause of vulnerability

    Time frame: Around the time of study procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2030, 73 months after the start.

Of 107 non-industry observational studies under Hip Fractures, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 65. This study's planned 73 months is above that.

Counting every sponsor, half of 124 studies reached it within 28 months; a quarter within 12 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Jul 31, 2026
StartActual
Nov 13, 2024
Primary completionEst.
Dec 30, 2030
CompletionEst.
Dec 30, 2030
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07740239
Lead sponsor
Tampere University Hospital
Responsible party
Otso Arponen (Adjunct professor, MD, Tampere University Hospital) — Principal investigator
First posted
Jul 31, 2026
Start date
Nov 13, 2024
Primary completion
Dec 30, 2030 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Jul 31, 2026

Study contacts

Otso Arponen, Adjunct professor, MD
Contact
otso.arponen@tuni.fi
504106170 ext. +358

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hip Fractures →

Other studies from this sponsor

Tampere University Hospital →

Start the discussion